DOI:
https://doi.org/10.7439/ijpr.v6i2.2883
Keywords:
Momordica charantia Linn., Diabetes mellitus, Terpenoids, Charantin
Abstract
Background: Diclofenac is the most commonly used non-steroidal anti-inflammatory drug (NSAID) for treating various inflammatory and painful conditions. It is generally well tolerated; gastric upset is the most common adverse effect. However very few cases of fixed drug eruptions were reported. Here we present a case of . A 62 year old male patient developed fixed drug eruptions with plaques on left thigh two days after receiving diclofenac for osteoarthritic pain. Other etiologies including insect bite, infections were ruled out. One week later after stopping the drug, the lesions were subsided. Diclofenac was strongly suspected as the casual drug. CD8+ effector T-cells have shown to play an important role. However it seems to be a reversible and drug related event. Although it is not life-threatening, fixed drug eruption can have significant effect on the quality of life of patients. Conclusion: Diclofenac is one of the most commonly prescribed NSAIDs by the Physicians. It is usually well tolerated, gastric upset is the most common adverse effect noted with this drug. This case is being reported to highlight a drug as safe as Diclofenac may also be associated with Fixed Drug Eruptions.
Downloads
References
Guptha SD, Prabhakar SM, Sacchidanand S. Fixed drug eruption due to levocetirizine. Indian J Dermatol Venereol Leprol. 2005; 71:361–2.
Malheiro D, Cadinha S, Rodrigues J, Vaz M, Castel-Branco MG. Nimesulide-induced fixed drug eruption. Allergol Immunopathol. 2005; 33:285–7.
Goodman Gilman. The Pharmacological Basis of Therapeutics. McGraw-Hill Publication 12th Edition; 2011Chapter 34:986.
Shiohara T and Mizukawa Y. Fixed drug eruption: A disease mediated by self-inflicted responses of intraepidermal T cells. Europian Journal of Dermatology 2007; 17: 201-208.
Shiohara T, Nickoloff BJ, Sagawa Y et al., Fixed drug eruption. Expression of epidermal keratinocyte intercellular adhesion molecule-1 (ICAM-1), Arch Dermatol, 1989; 125: 1371-1376.
Shiohara T, Mizukawa Y, Fixed drug eruption: a disease mediated by self inflicted responses of intraepidermal T cells, Eur J Dermatol, 2007; 17: 201-208.
Shiohara T, Mizukawa Y, Teraki Y, Pathophysiology of fixed drug eruption: the role of skin resident T cells, Curr Opin Allergy Clin Immunol, 2002; 4: 317-323.
Chatterjee S, Ghosh AP, Barbhuiya J and Dey SK. Adverse cutaneous drug reactions: A one year survey at a dermatology outpatient clinic of a tertiary care hospital. Indian Journal of Pharmacology 2006; 38: 429-431.
Goodman Gilman. The Pharmacological Basis of Therapeutics. McGraw-Hill Publication 12th Edition; 2011 Chapter 34:959.
Lakshmi C and Srinivas CR. Systemic (allergic) contact dermatitis to diclofenac. Indian Journal Dermatology Venereology and Leprology 2011; 77- 536.
Sehgal VN, Srivastava G, Fixed drug eruption (FDE): changing scenario of incriminating drugs, Int J Dermatol, 2006; 45: 897-908.
- PDF
Published
How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
-
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Author must Submit Copyright form After acceptance of Article
